touchLearning Activities
Education, Conference Coverage and Articles
Two EFFISAYIL ON analyses presented at EADV 2026 highlight complementary roles for subcutaneous and intravenous spesolimab in generalized pustular psoriasis. During long-term subcutaneous treatment, 17 of 20 patients remained flare-free during follow-up. In a separate analysis, pustules were clear at Week 1 in half of the 36 breakthrough flares treated with intravenous spesolimab.
Drug repurposing could offer new treatment opportunities for rare genetic skin diseases. Prof. Dédée Murrell discusses the rationale for exploring existing medicines, progress in epidermolysis bullosa, and how a new trial aims to match treatments to patients’ inflammatory profiles rather than their genetic subtype.
What did the Women’s Dermatologic Society bring to EADV 2026? Explore session highlights spanning blistering diseases, skin cancer, scarring alopecias, and more. Prof. Dedee Murrell introduces the society’s focus on mentorship, explains why the session is worth watching, and shares why dermatologists should consider joining.
What were the key dermatology updates at EADV 2026? Dr Melinda Gooderham shares her highlights, exploring the Janus kinase (JAK) inhibitors session, new data comparing zasocitinib with deucravacitinib, and 2-year findings from ICONIC-TOTAL evaluating icotrokinra.
Part B of the phase 2 APEX trial evaluated three zumilokibart dosing regimens in adults with moderate-to-severe atopic dermatitis. All three met the primary endpoint at Week 16, with findings supporting mid dose selection for phase 3. Dr Melinda Gooderham discusses the efficacy and safety results from both Part A and Part B and what they could mean for clinical practice and those living with AD.
Could abdakibart offer a new treatment option for hidradenitis suppurativa? Dr Martina L. Porter discusses encouraging findings from the phase 2 LOTUS trial, including improvements in disease severity and draining tunnels, alongside a reassuring safety profile over 16 weeks, and considers what these results could mean for clinical practice.
For women taking dupilumab to manage atopic dermatitis or asthma, limited pregnancy safety data can make treatment decisions challenging. Dr Christina Chambers discusses reassuring findings from a registry study of 539 pregnancies and how they could help clinicians counsel women who are pregnant or planning a family.
Sonelokimab showed encouraging results in the phase 2 LEDA trial in adults with palmoplantar pustulosis. Dr Nina Magnolo discusses the findings, including a mean 64% reduction in disease severity at Week 16, and their potential implications for patients.
On Day 2 of the EADV 2026 congress, we were delighted to speak with touchDERMATOLOGY Editorial Board member, Dr Maria Angeliki Gkini who shared her highlights from key psoriasis sessions and discussed what these developments could mean for clinical practice.
New 52-week REZOLVE-AD data showed durable responses with monthly and quarterly rezpegaldesleukin (REZPEG) maintenance dosing in atopic dermatitis. Prof. Thomas Bieber discusses the findings and the potential for long-term remission and disease modification, highlighting the further evidence needed to explore these goals.
Could glucagon-like peptide-1 receptor agonists affect nail health? A multinational study presented at EADV 2026 found nail disorders were reported more frequently among users, with nearly sevenfold higher odds of nail detachment. Prof. Bianca Maria Piraccini discusses the findings and why further clinical assessment is needed.
From pruritus and burn scars to cutaneous neurofibromas, Prof. Ashraf Badawi explores some of the new directions for lasers and energy-based devices discussed at this years EADV congress.
How does bimekizumab perform in everyday clinical practice? An Italian multicenter study reported improvements in disease activity, pain, and quality of life in people with hidradenitis suppurativa, with no unexpected safety signals. Dr Mario Valenti shares the findings and his perspective with touchDERMATOLOGY.
Encouraging findings from JAKPPPOT support the feasibility of a definitive randomized controlled trial of Janus kinase inhibitors in palmoplantar pustulosis and provide an exploratory estimate of treatment effect. We spoke with Dr David Gleeson about the results presented at EADV 2026 and their implications for future research.
RLS-1496 1% cream (Rubedo Life Sciences, CA, USA) is an investigational senotherapeutic treatment that selectively and potently inhibits the antioxidant enzyme glutathione peroxidase 4 (GPX4). It aims to target senescent cells, potentially offering a new approach to treating AK.2 Results from a phase 1b/2a, multicenter, open-label clinical study of RLS-1496 1% cream were presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Congress 2026.
Dr Maria-Angeliki Gkini explores the growing role of psychodermatology in supporting patients’ wider needs, alongside emerging technologies and approaches that could shape the future management of psoriatic disease.
touchDERMATOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
